Article Figures & Data
Tables
- TABLE 1
Clinical Pharmacogenetics Implementation Consortium drug-gene pairs with evidence-based guidelines
Drugs Genes Abacavira HLA-B*57:01 Allopurinol HLA-B*58:01 Amitriptylinea CYP2C19, CYP2D6 Atazanavir UGT1A1 Atomoxetinea CYP2D6 Azathioprinea TPMT, NUDT15 Capecitabinea DPYD Carbamazepinea HLA-A*31:01, HLA-B*15:02 Citaloprama CYP2C19 Clomipraminea CYP2C19, CYP2D6 Clopidogrela CYP2C19 Codeinea CYP2D6 Desipraminea CYP2D6 Doxepina CP2C19, CYP2D6 Efavirenz CYP2B6 Escitalopram CYP2C19 Fluorouracila DPYD Fluvoxamine CYP2D6 Imipraminea CYP2C19, CYP2D6 Ivacaftor CFTR Mercaptopurinea TPMT, NUDT15 Nortriptylinea CYP2D6 Ondansetron CYP2D6 Oxcarbazepinea HLA-B*15:02 Paroxetine CYP2D6 Peg-interferon alfa-2a IFNL3 (IL28B) Peg-interferon alfa-2b IFNL3 (IL28B) Phenytoina CYP2C9, HLA-B*15:02 Rasburicase G6PD Ribavirin IFNL3 (IL28B) Sertraline CYP2C19 Simvastatin SLCO1B1 Succinylcholine RYR1, CACNA1S Tacrolimus CYP3A5 Tamoxifen CYP2D6 Tegafur DPYD Thioguaninea TPMT, NUDT15 Trimipraminea CYP2C19, CYP2D6 Tropisetron CYP2D6 Volatile anesthetics RYR1, CACNA1S Voriconazole CYP2C19 Warfarina CYP2C9, CYP4F2, VKORC1 ↵a The drug also has US Food and Drug Administration-designated pharmacogenetic labeling as a boxed warning, a contraindication, a warning and precaution, or a dosing and administration recommendation.
From the Clinical Pharmacogenetics Implementation Consortium, https://cpicpgx.org/genes-drugs.
In this issue
Jump to section
- Article
- ABSTRACT
- WHAT ARE PHARMACOGENES?
- CLINICAL UTILITY OF PHARMACOGENOMICS
- OPIOIDS AND CYP2D6
- ANTIDEPRESSANTS AND CYP2D6, CYP2C19, SLC6A4, HTR2A, AND HTR2C
- CLOPIDOGREL AND CYP2C19
- OTHER CLINICAL CONSIDERATIONS
- ADDRESSING CHALLENGES TO PHARMACOGENOMIC TESTING
- IS PHARMACOGENOMIC TESTING COST-EFFECTIVE?
- DIRECT-TO-CONSUMER TESTING
- EDUCATION AND INFRASTRUCTURE NEEDED
- DEVELOPING PHARMACOGENOMIC SERVICES
- POISED TO IMPROVE CARE
- Footnotes
- REFERENCES
- Figures & Data
- Info & Metrics